Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;27(6):771-8.
doi: 10.1111/j.1468-3083.2012.04582.x. Epub 2012 Jun 1.

Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases

M Afshar  1 , A D Martinez, R L Gallo, T R Hata
Affiliations
Review

Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases

M Afshar et al. J Eur Acad Dermatol Venereol. 2013 Jun.

Abstract

Background: Interferon-alpha (IFN-α) therapy is used to treat hepatitis C infection. The exacerbation and occurrence of psoriasis in hepatitis C patients treated with IFN-α is increasingly recognized, but the distinct associated features, aetiology and management have not been reviewed.

Objective: To review all published cases of hepatitis C patients who developed psoriasis while receiving IFN-α therapy.

Methods: The review was conducted by searching the PubMed database using the keywords 'hepatitis C' AND 'psoriasis.' In addition, references to additional publications not indexed for PubMed were followed to obtain a complete record of published data.

Results: We identified 32 publications describing 36 subjects who developed a psoriatic eruption while receiving IFN-α therapy for hepatitis C. Topical therapies were a commonly employed treatment modality, but led to resolution in only 30% of cases in which they were employed solely. Cessation of IFN-α therapy led to resolution in 93% of cases. Hundred per cent of those who developed psoriasis while on IFN-α therapy responded to systemic therapy and were able to continue the drug.

Conclusion: Further studies and analysis of IFN-α-induced lesions are necessary to clarify the role of IFN-α and the hepatitis C virus in the development of psoriatic lesions.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None declared.

Figures

Figure 1
Figure 1
New-onset plaque psoriasis on the (a) lower abdomen at pegIFN-α injection sites and (b) knees of a 57-year-old male with a one-year history of hepatitis C (HCV RNA 0 at presentation). Lesions appeared 4 weeks into pegIFN-α treatment.
Figure 1
Figure 1
New-onset plaque psoriasis on the (a) lower abdomen at pegIFN-α injection sites and (b) knees of a 57-year-old male with a one-year history of hepatitis C (HCV RNA 0 at presentation). Lesions appeared 4 weeks into pegIFN-α treatment.
Figure 2
Figure 2
A model for the role of exogenous IFN-α treatment in the pathogenesis of psoriasis. Adapted from [95].
See this image and copyright information in PMC

References

    1. Edlin B. Five million Americans infected with the hepatitis C virus: a corrected estimate. Hepatology. 2005;42(4 Suppl 1):44. - PubMed
    1. Ghany MG, et al. Diagnosis, management, and treatment ofhepatitis C: An update. Hepatology. 2009;49(4):1335–1374. - PMC - PubMed
    1. Armstrong GL, et al. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Annals of Internal Medicine. 2006;144(10):705–714. - PubMed
    1. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(5B):s30–s34. - PubMed
    1. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. Journal of Hepatology. 1999;31 Supplement 1(0):17–24. - PubMed

Publication types